Mexican pharma exports to the U.S. (mostly generics and OTC) are excluded from Section 232 pharma effective July 31. Most Mexican-produced pharma can qualify under USMCA tariff-shift rules – exempting from Section 122 plus providing preferential base rates. FDA admission applies separately.
This guide covers Mexico Pharma Exports to the U.S.. For SMB importers and exporters, the practical implementation depends on volume, sector, and operational structure.
For background, see /usmca-cusma/ and our complete cross-border practice.
Section 232 pharma exclusion
Generics and biosimilars excluded under current proclamation. Most Mexican pharma export is generic.
USMCA pharma qualification
Tariff-shift from API to FDF in Mexico supports USMCA origin. Section 122 exempt; preferential base rates.
FDA admission process
Mexican pharma must meet FDA registration, listing, and (where applicable) premarket clearance requirements separate from CBP entry.
Documentation
Manufacturing process flowcharts, supplier certificates for APIs and excipients, USMCA Certificate of Origin, FDA registration.
Frequently asked questions
When is this most relevant?
For SMB importers/exporters in cross-border operations or those with active sourcing/distribution decisions to make.
What documentation is needed?
CBP Form 7501, supplier certificates, BOM analysis, country-of-origin documentation, USMCA/CUSMA Certificate of Origin where applicable.
Can you handle the full setup?
Yes. End-to-end engagements ranging from $3,500-$15,000 depending on complexity. Ongoing retainer for active operations.
What’s the typical timeline?
Simple cases 2-4 weeks; complex cross-jurisdiction setups 6-12 weeks.
How do I begin?
Book a 15-minute scoping call. We confirm fit and scope before any engagement.
Get started
Book a Mexico cross-border tariff consultation. Bilingual capability.